Carisma Therapeutics (NASDAQ:CARM) has appointed Drs. Scott Friedman and Ira Tabas to its scientific advisory board (SAB).
“It is an honor to welcome Dr. Friedman and Dr. Tabas to our SAB,” said Steven Kelly, president and CEO of Carisma. “Their extensive experience and groundbreaking research in liver fibrosis will significantly enhance our efforts in developing innovative engineered macrophage therapies for advanced liver disease. We are excited to collaborate with them and benefit from their profound expertise.”
Scott Friedman, MD, is the chief emeritus of liver diseases at the Icahn School of Medicine at Mount Sinai in New York.
Ira Tabas, MD, Ph.D., is the Richard J. Stock professor and vice-chair of research in the Department of Medicine, and professor pathology and cell biology (in Physiology and Cellular Biophysics) at Columbia University in New York City.
Both Dr. Friedman and Dr. Tabas bring extensive expertise and renowned pioneering contributions in liver fibrosis to Carisma’s SAB.
